{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.8"},{"groupId":"OG001","value":"33.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"129"},{"groupId":"OG001","value":"113"}],"units":"Participants"}],"description":"No. of patients who were objective responders over the no. of patients evaluable for response x100. An objective responder = a patient whose best response is either CR (disappearance of all lesions) or PR (\\>= 30% shrinkage in the sum of the longest diamemeters of the measurable lesions + no new lesions + no progression of non-measurable lesions)","groups":[{"description":"Fulvestrant 250 mg Loading Dose Regimen + Anastrozole 1 mg","id":"OG000","title":"Fulvestrant + Anastrozole"},{"description":"Anastrozole 1 mg","id":"OG001","title":"Anastrozole"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"RECIST tumour assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009","title":"Percentage of Evaluable Participants With Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Percentage of evaluable participants"}